Nature Medicine, Published online: 17 April 2025; doi:10.1038/d41591-025-00026-8
Despite a negative primary outcome, a trial of gantenerumab showed a clinically meaningful slowing of disease onset in asymptomatic people who were treated for the longest duration.
Comments
No Trackbacks.